Correction to #msg-65857564—NVS’ operating margin on Lovenox was 69% (not 66%); MNTA’s profit share from Lovenox was $87.6M (not $83.8M) because there was a $3.7M contractual true-up of accounts in the NVS-MNTA collaboration following the first year of the product launch. (Source: MNTA’s CC)
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.